Journal of Clinical Oncology
Articles in this Issue
Real-world data on post-neoadjuvant trastuzumab emtansine to benchmark DESTINY-Breast-05 and -11 emerging paradigms.
e12516 Background: Post-neoadjuvant trastuzumab emtansine (T-DM1) is the standard of care for patients (pts) with HER2-pos...
Prevalence of neurologic death in NSCLC patients with brain metastases treated with radiosurgery in the modern treatment era.
e20698 Background: Immune checkpoint blockade (ICB) and molecularly targeted therapies are increasingly integrated into th...
Efficacy with fruquintinib plus sintilimab versus axitinib or everolimus in advanced renal cell carcinoma: A post-hoc analysis from FRUSICA-2 trial by baseline tumor burden.
4533 Background: The multicenter randomized phase 2/3 FRUSICA-2 trial (NCT05522231) demonstrated that fruquintinib plus si...
National analysis of facility-level survival differences in elderly splenic marginal zone lymphoma patients.
e13740 Background: Splenic marginal zone lymphoma (SMZL) is an uncommon indolent B-cell lymphoma primarily affecting older...
Survival outcomes of neoadjuvant versus adjuvant chemotherapy in stage II-III hormone receptor-positive/HER2-negative breast cancer: A propensity score–matched analysis.
e12673 Background: The role of neoadjuvant chemotherapy (NACT) in stage II-III hormone receptor-positive and HER2-negative...
Overall survival after stereotactic radiosurgery versus whole-brain radiotherapy for patients with ≥5 brain metastases: A systematic review and meta-analysis.
e14017 Background: The role of stereotactic radiosurgery (SRS) is well established in the setting of one to four brain met...
Structural determinants compared with genetic ancestry and self-reported race in triple-negative breast cancer disparities: A multilevel analysis in an admixed population.
617 Background: Triple-negative breast cancer (TNBC) exhibits marked racial disparities in outcomes. However, the contribu...
Ultra-refractory PD–PD pancreatic cancer: Clinical and molecular insights across first- and second-line therapy.
4206 Background: A subset of pancreatic cancer (PC) patients exhibits progressive disease (PD) as the best response to bot...
Are younger patients considered?: Geographic access and age-focused design in advanced PDAC trials for Appalachian populations.
e16384 Background: Younger-onset pancreatic ductal adenocarcinoma (PDAC) represents a clinically distinct population with...
SigVie-003: Phase 3 trial of frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab alone in non-small cell lung cancer (NSCLC) with PD-L1 TPS ≥50%.
TPS8660 Background: Integrin beta-6 (IB6) is a tumor-associated membrane protein linked to poor outcomes in solid tumors,...
Effect of time to treatment initiation in MCL: A SEER analysis from 2000-2022.
e23069 Background: Mantle Cell Lymphoma (MCL) is a rare subtype of Non-Hodgkin Lymphoma (NHL) with a heterogeneous clinica...
Phase III randomized trial of tislelizumab plus gemcitabine/capecitabine (GX) versus tislelizumab plus gemcitabine/cisplatin (GP) as first-line therapy for recurrent/metastatic nasopharyngeal carcinoma: A prospective multicenter study (PROGRESS).
TPS6125 Background: Nasopharyngeal carcinoma (NPC) is a prevalent malignancy in Southeast Asia and Southern China. Around...
Trends and characteristics of clinical trials presented in ASCO plenary sessions (2011–2025).
11024 Background: Clinical trials presented during the ASCO Annual Meeting Plenary Session (PS) represent a curated subset...
Real-world comparison of anti-GPRC5D bispecific therapy versus anti-BCMA treatment in relapsed/refractory multiple myeloma after prior BCMA-directed therapy.
e19509 Background: In relapsed/refractory multiple myeloma (RRMM), B-cell maturation antigen (BCMA)-directed therapies (BD...
Creating affordable and accessible cancer care at scale: History of extension from 12 to 750 districts, covering the whole of the nation—India.
e13599 Background: The principal challenges in cancer care are the affordability, accessibility, and availability of an ad...
Intensive chemotherapy versus venetoclax–hypomethylating agents therapy for acute myeloid leukemia: A large real-world propensity-matched study.
e18541 Background: Intensive induction chemotherapy (IC) with cytarabine and an anthracycline has been the frontline appro...
Influence of neoadjuvant therapy on tumor-vascular-immune stromal networks in colorectal cancer liver metastases.
3586 Background: Neoadjuvant therapy's effect on vascular, tumor, and immune compartments, and their co-regulation, in col...
Influence of socioeconomic factors on patient-reported provider communication among patients with cancer.
12091 Background: Patient-provider communication is central to patient’s understanding and overall experience, particularl...
Uniportal versus multiportal video-assisted thoracic surgery (VATS) in esophageal cancer: A systematic review and meta-analysis.
e16114 Background: Minimally invasive approaches are increasingly used in esophageal cancer surgery, but the relative bene...
Uncovering prostate cancer and sepsis-related mortality shifts in the USA (1999-2020).
e17104 Background: Prostate cancer is a commonly diagnosed malignancy among men. Sepsis continues to pose a significant th...
Evaluating AFP–liver reserve discordance and microvascular invasion in resected and transplanted hepatocellular carcinoma.
e16262 Background: The prognosis of hepatocellular carcinoma (HCC) is influenced by tumor biology and liver function. Mism...
Prevalence and fracture burden of osteoporosis among patients with colorectal cancer: A real-world analysis.
11170 Background: Osteoporosis is a common age-related skeletal disorder that may be underrecognized among patients with c...
Trends in mortality involving esophageal cancer and alcohol-related behavioral disorders in the United States, 1999–2023.
e16071 Background: Esophageal cancer carries one of the highest mortality rates among solid tumors, while alcohol-related...
Bone marrow metastasis in prostate cancer: Treatment feasibility and survival in a real-world cohort.
e17051 Background: Bone marrow metastasis (BMm) in prostate cancer (PCa) is a rare and life-threatening condition, typical...
Quantifying the macroeconomic burden of cancer: Global disparities in value-of-lost-welfare (VLW).
10580 Background: Cancer (CA) remains a leading global driver of disability and premature death, yet its full macroeconomi...